09 jun: Syv 18-hullers baner midt i paradis
10 jun: Overskud i APM´s containerforretning
09-06-2012 16:14:00

Clinical Studies Show New, Proposed J&J Diabetes Drug Cuts Blood Sugar

Relateret indhold

By Jennifer Corbett Dooren

WASHINGTON--Data from advanced clinical studies of a new type of diabetes drug being developed by a unit of Johnson & Johnson (JNJ) showed it reduced a measure of blood sugar in patients with type 2 diabetes.

The drug, canagliflozin, was studied in nine so-called Phase 3 studies, which are needed to support regulatory approval of products.

Information from five of the studies will be presented this weekend at the American Diabetes Association's annual meeting and will provide the first in-depth look at the drug. So far the U.S. Food and Drug Administration has refused to approve a similar drug, dapagliflozin, from Bristol-Myers Squibb Co. (BMY) and AstraZeneca PLC (AZN) and has asked the companies for more information to assess risks and benefits.

Broadly the canagliflozin studies show the drug was better than or similar to other diabetes drugs at reducing blood sugar. Overall side-effect rates were similar among patient groups.

Janssen Research and Development LLC, part of J&J, submitted an application with the FDA seeking approval of canagliflozin on May 31. It is the first time Johnson & Johnson has sought FDA approval of a diabetes drug. Other J&J units sell diabetes devices like blood-glucose meters.

"We studied the drug in a broad range of patients," said Kirk Ways, vice president and compound development leader for canagliflozin. "We feel the benefit-risk profile is good." Canagliflozin is in a new class of drugs called sodium-glucose co-transporter-2 (SGLT2) inhibitors. Such drugs are designed to lower blood glucose levels in patients with diabetes by increasing the amount of glucose excreted in the urine. The SGLT2 system is used by the kidneys to filter and reabsorb glucose circulating in the blood.

Dr. Ways explained that currently available diabetes treatments work in different ways to lower blood sugar, so canagliflozin could potentially be added to those drugs. Diabetes is a progressive disease that usually requires treatment with different types of drugs.

One of the canagliflozin studies involved patients whose blood sugar was inadequately controlled on metformin, typically the first drug given to treat type 2 diabetes. The study compared two doses of canagliflozin to patients being given glimepiride, a drug often used once metformin stops working.

The main study goal was to look at changes in A1C blood hemoglobin levels, a common measurement of blood glucose. The 1,450 patients in the study had an average A1C of 7.8% at the study's start. After one year, the study showed the 100 milligram dose of canagliflozin was similar to patients being treated with glimepiride by reducing blood sugar levels to an average of 7%. The higher, 300 milligram dose of canagliflozin reduced average blood sugar levels by nearly a full percentage point.

People without diabetes typically have an A1C level below 6%. Diabetes treatments are aimed at reducing blood sugar levels to 7% or below.

The other study involved 755 people who didn't have good blood-sugar control on metformin and a sulfonylurea drug, such as glimepiride. Patients had an average A1C of 8.1% at study start. Patients were treated with the highest, 300 milligram dose of canagliflozin or sitagliptin, sold as Januvia by Merck & Co. (MRK). Januvia is a newer diabetes medication that works in a different way than metformin and sulfonylurea drugs. After one year the study showed patients on canagliflozin had drops in blood sugar levels of a full percentage point while those in the Januvia group had a decline of 0.66%.

However, both studies showed patients receiving canagliflozin had a higher rate of genital infections and reports of more frequent urination than patients in comparison groups. Dr. Ways said the infections were effectively treated with topical or oral anti-fungal medications and said most patients did not stop taking canagliflozin.

Diabetes affects about 26 million Americans and is characterized by high blood glucose levels caused by the body's inability to either make or properly use insulin. Type 2 diabetes is the most common form of the disease and is often associated with weight gain and older age. Type 1 is an autoimmune disease often diagnosed in children in which the body's immune system destroys pancreatic beta cells that produce insulin.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com

(END) Dow Jones Newswires

June 09, 2012 10:14 ET (14:14 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12 feb
JNJ
På dagschart ligner det hold for gult, og vend om i wedge igen   https://invst.ly/6m8hg   på ugecha..
4
12 feb
JNJ
CHR. Hansen ser ud til at følge Novo retningen, tror jeg vil overveje at genkøbe den også ;)   https..
3
12 feb
JNJ
Tak for graferne. Den har tydeligt besvær lige over 130 her på den korte bane. Spændende om den rive..
2
12 feb
JNJ
Genmab har næsten testet dobbelt-bund i 985,50 og laver pt. backtrace op, men under forsat salgssign..
1
12 feb
JNJ
Jeg er ikke interesseret i J&J, kender den ikke godt nok.   Men andre mener den er god   Best buying..
1
12 feb
JNJ
JNJ er egentligt gået i teknisk nedtrend idet aktien nu handles under MA200. Jeg har alligevel købt ..
1

Fondsbørsmeddelelser

Nordea/Nykredit: Mindre gevinst ved flytningen betyder ikke meget

16-02-2018 16:17:10
Ændringen i besparelserne ved Nordeas flytning til Finland fra Sverige betyder ikke frygtelig meget.Det vurderer analytiker ved Nykredit Markets Ricky Steen Rasmussen.Forventningerne til besparelserne i forbindelse med flytningen til Finland er blevet justeret til 0,9-1,2 mia. euro fra 1,1-1,3 mia. euro. Det oplyste Nordea i en meddelelse til fondsbørsen fredag eftermiddag.- Jeg ser ikke særlig st..

Nordea venter færre besparelser ved flytning til Finland

16-02-2018 14:18:54
Efter nøje beregninger er Nordea kommet frem til, at den forestående flytning af hovedsædet til Finland fra Sverige giver en mindre økonomisk gevinst end hidtil antaget.Nu venter den skandinaviske storbank, at nettonutidsværdien af de samlede besparelser på afviklingsgebyrer, indskydergarantier og andre midlertidige effekter af flytningen af hovedsædet udgør cirka 0,9-1,2 mia. euro. Tidligere regn..

Aktier/middag: Bred funderet opgang er modreaktion på korrektion

16-02-2018 11:19:57
De ledende danske aktier ligger fredag middag alle i grønt uden deciderede selskabsspecifikke faktorer som forklaring på de enkelte aktiers bevægelser.I toppen ligger Novozymes, Novo Nordisk og DSV.C25-indekset ligger fredag middag med en stigning på 1,9 pct. i 1142,72. Det er tredje dag i træk med løft, og indekset er indtil videre steget fire af de seneste fem handelsdage og små 5 pct. siden sid..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Hartmann: Direktør Ulrik Kolding Hartvig død efter cykelulykke
2
Briter har 10 dage til at bruge 1,8 milliarder kroner - citat
3
Lettisk nationalbankdirektør er anholdt af korruptionspoliti
4
Briterne ønsker sikkerhedstraktat med EU inden 2019
5
Japans eksport steg noget mere end ventet i januar

Relaterede aktiekurser

Bristol-Myers Squibb Com.. 68,96 0,0% Aktiekurs uændret
Johnson & Johnson 133,15 0,0% Aktiekurs uændret
Astrazeneca PLC ORD SHS .. 4.739,50 0,0% Aktiekurs uændret
Astrazeneca PLC 33,93 0,0% Aktiekurs uændret
AstraZeneca PLC 537,80 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. februar 2018 08:39:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180209.1 - EUROWEB6 - 2018-02-19 08:39:42 - 2018-02-19 08:39:42 - 1 - Website: OKAY